Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2005

View Archived Issues

Draxis amalgamates two subsidiaries

Alliance and LEO Pharma to enter Oxygent agreement for Europe and Canada

Positive results from confirmatory phase III study of Lauriad

Topline results of phase III orBec study

Nippon Kayaku to develop IL13-PE38QQR in Japan

Phase III protocol submitted for Multikine

Enrollment completed in Rebif vs. Copaxone comparative study

Phase I/II trial for TG-100-115 in heart attack patients

Vitae Pharmaceuticals, new name for Concurrent

Stellar International changes name to Stellar Pharmaceuticals

Phase Ib trials commence for next-generation Panzem

Treatment begins in phase I study of IMC-1121B in patients with solid tumors

Positive preclinical findings for Zeatin and cytokinin compounds

Arylchloroethylurea derivative exhibits antitumor activity in colon cancer model

Abraxane approved for metastatic breast cancer

ISTA launches Vitrase

Antithrombotic effects of fluvastatin tested in vitro

Rotarix launched in Mexico

Acute and chronic treatment with JTE-607 is effective in a mouse septic shock model

Rotigotine patch effective in moderate to severe restless legs syndrome

Macrolide antiinflammatory agents patented by Pliva

CRF-1 receptor antagonists in early development at Pfizer

Merck patent discloses synthesis of novel chemokine CCR2 receptor modulators

Phospholipase inhibitors prepared and tested at Lilly

Elan/Pfizer collaboration produces novel BACE inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...